From first step to final outcome: Reframing feasibility as an operational strategy

  • ow integrating cross-functional risk assessment of the feasibility process can enhance site strategy, clinical oversight, system selection(s) product solutions, and long-term trial delivery
  • How to identify feasibility approaches that align with execution, not just enrollment, and how a more connected model helped de-risk a complex study
  • Practical strategies to elevate feasibility from a planning task to a foundational element of trial success
  • Understand the difference between traditional feasibility and true operational feasibility, and why that distinction matters
  • Learn how early cross-functional risk assessments can expose delivery risks before they surface mid-study
  • Discover how to align feasibility insights with cross-functional oversight, site strategy, and fit-for-purpose systems with customized solutions from the outset
  • Explore how an integrated feasibility-to-delivery model can improve performance in high-complexity, high-variability trials

PANEL: Running clinical trials in different geographical regions: benefits of running trials inside vs outside the US

  • With uncertainty and constant change in the US, is the solution to look overseas for clinical trial sites?
  • Working with CROs and partners overseas: assessing benefits as well as potential challenges
  • Positive and negative impacts of trials abroad on clinical trial finances and budgeting
  • What advantages are there of keeping trials inside the US?

MODERATOR Revati Tatake, Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData Healthcare

PANEL: Strengthening supplier relationships: strategies for positive collaboration and communication

  • Fostering transparent and constant communication with CROs and other suppliers to minimize delays and ensure timelines stay on track
  • Ensuring your suppliers’ goals align with your study goals
  • Monitoring CRO and supplier performance with clearly defined KPIs
  • Aligning on project timelines, milestones and quality expectations from the beginning

MODERATOR
Rich Polgar, Managing Director, Danforth Advisors

FIRESIDE CHAT: Keeping patients and caregivers at the center of rare disease clinical trials: collaborating with patients, caregivers, and nonprofits for better outcomes

  • Understanding the provider-patient conversations: point-of-patient and provider discussions to shape trial design that is patient centric
  • Survey design: creating questions focused on patient and caregiver needs during the trial and post-trial to keep patients engaged and enrolled leading to better outcomes
  • Share your Rare Action: mention your post-session action to improve your process that includes rare patients, caregivers, and non-profits